HBOT for Cognitive Function and Brain Fog: What the Research Shows

The short answer: In the first randomized controlled trial of hyperbaric oxygen therapy (HBOT) in healthy older adults (Hadanny et al., Aging, 2020), 60 sessions at 2.0 ATA significantly improved global cognition (group-by-time p=0.0017), with the largest gains in attention and information processing speed (net effect sizes 0.745 and 0.788) — alongside measured increases in cerebral blood flow. That is real evidence for specific cognitive domains, not proof that HBOT “cures brain fog.”

“Brain fog” is now one of the most common reasons people walk into a hyperbaric clinic. The marketing promises sharper focus and a clearer head; the science is more specific and more interesting than the slogans. This guide separates what HBOT has measurably done to cognition in controlled trials — including fresh 2025–2026 data — from what the wellness claims imply.

Disclosure: Superhuman Chambers manufactures and sells hyperbaric chambers for wellness operators. This article summarizes published research and is not medical advice. Brain fog can signal a treatable medical condition; see a clinician before assuming any single therapy is the answer.

What “Brain Fog” Actually Is (and Isn’t)

Brain fog is a description of a symptom, not a diagnosis. As Harvard Health puts it, “brain fog is not a medical or scientific term; it is used by individuals to describe how they feel when their thinking is sluggish, fuzzy, and not sharp.” Cleveland Clinic frames it the same way: a group of symptoms affecting thinking, memory, and concentration, commonly reported after COVID-19 and chemotherapy.

That distinction matters before anyone books a course of HBOT. Brain fog is usually downstream of something else, and several of those causes are common and treatable:

• Poor sleep and untreated obstructive sleep apnea
• Stress, anxiety, and depression
• Thyroid dysfunction (an underactive thyroid)
• Low vitamin B12 and other nutritional gaps
• Medication side effects
• Hormonal changes

The honest first step is diagnostic, not therapeutic: rule out the fixable causes. HBOT has been studied for the cognitive symptoms of specific conditions — aging, post-COVID syndrome, traumatic brain injury, stroke — not for “brain fog” as a stand-alone complaint. The research below is organized around those populations, because that is where the data actually exists.

How HBOT Acts on the Brain

HBOT raises ambient pressure above one atmosphere and delivers 100% oxygen, dissolving far more oxygen into blood plasma than ordinary breathing. The therapeutic trigger is the hyperoxic-hypoxic paradox: repeated, intermittent spikes of high oxygen followed by a return to baseline are read by the body as if it were oxygen-starved, switching on regenerative pathways without any actual injury.

In the brain, that cascade drives the mechanisms most relevant to cognition:

• Increased cerebral blood flow (CBF) — the 2020 healthy-aging trial documented regional CBF increases on perfusion MRI in frontal and parietal areas (Brodmann areas 6, 7, 8, 9, and 10) that govern attention and executive control.
• Angiogenesis — formation of new blood vessels, restoring microcirculation in under-perfused tissue.
• Neuroplasticity — the post-COVID and post-stroke trials reported imaging changes (SPECT, DTI, prefrontal functional connectivity) consistent with structural and functional brain remodeling.
• Reduced neuroinflammation and improved mitochondrial function — proposed mechanisms in the traumatic brain injury literature.

These are the plausible biological levers. Whether they translate into measurable cognitive change is the question controlled trials have started to answer.

The Healthy-Aging Trial: Cognition in Adults Over 64

The strongest evidence that HBOT can shift cognition in people without a neurological diagnosis comes from a randomized controlled trial at Shamir Medical Center in Israel (Hadanny et al., Aging, 2020). It enrolled 63 healthy adults over 64, randomized to HBOT (n=33) or a control arm (n=30) for three months. The protocol was 60 daily sessions, 2.0 ATA, 90 minutes of 100% oxygen, five days a week.

The results were domain-specific rather than a blanket “smarter” effect:

The authors concluded that HBOT can “induce cognitive enhancements in healthy aging adults” through mechanisms involving regional CBF changes — and notably, the domains that improved (attention, processing speed, executive function) are exactly the ones that normally decline with age. This is the result most often cited in longevity circles, and it is genuinely a first-of-its-kind finding. It is also a single trial from one research group, a caveat the closing sections return to.

Brain Fog After COVID: The Sham-Controlled Trial

Post-COVID “brain fog” produced the most rigorous HBOT cognition study to date: a randomized, sham-controlled, double-blind trial (Zilberman-Itskovich et al., Scientific Reports, 2022; NCT04647656). It enrolled 73 patients with post-COVID symptoms persisting at least three months, randomized to HBOT (n=37) or a convincing sham (n=36).

The sham control is what sets this trial apart: the control group entered the same chamber and breathed 21% oxygen at 1.03 ATA, while the HBOT group received 40 daily sessions, 2.0 ATA, 100% oxygen by mask for 90 minutes with five-minute air breaks every 20 minutes, five days a week over two months. Neither patients nor evaluators knew who got the real treatment.

Brain imaging (SPECT and DTI) showed changes the authors interpreted as neuroplasticity. Their conclusion: HBOT can improve the cognitive, psychiatric, fatigue, and sleep symptoms of post-COVID condition. The effect sizes here are medium — smaller than the healthy-aging trial — but they survive a sham comparison, which is the harder test. (We cover the broader symptom picture in our HBOT for long COVID recovery guide.)

The Evidence Keeps Growing (2025–2026)

The cognition research did not stop with those two trials. The most recent syntheses point in the same direction while keeping the caveats visible.

A 2025 systematic review and meta-analysis of HBOT for neurocognitive deficits after traumatic brain injury (Shahid et al., Annals of Medicine and Surgery, 2025) pooled four studies and 250 patients. Using a random-effects model on NeuroTrax scores, it found statistically significant improvement across every neurocognitive domain measured:

The randomized trials in that analysis carried a low risk of bias. (For HBOT after head injury specifically, see our HBOT for concussion recovery guide.)

A 2026 randomized controlled trial (Journal of NeuroEngineering and Rehabilitation, April 2026) tested HBOT combined with computerized cognitive training in patients with post-stroke cognitive impairment. Across four arms over 20 sessions in four weeks, the combined HBOT-plus-training group showed significantly greater improvement in MMSE total and subscores — orientation, registration, attention, recall, and visuospatial — and in functional independence (Barthel Index) than the other groups. Changes in prefrontal connectivity correlated with cognitive gains (r=0.552, p<0.001), reinforcing the neuroplasticity mechanism and hinting that HBOT may work best paired with active cognitive work, not as a passive fix. (More on the stroke evidence in our HBOT for stroke recovery guide.)

Pressure and Protocol: Why 2.0 ATA and Session Count Matter

Every cognition result above came from 2.0 ATA hard-shell protocols, not mild low-pressure setups. Pressure determines how much oxygen actually dissolves into plasma and reaches brain tissue.

The other variable is dose. The published cognition protocols cluster at 40 to 60 daily sessions — not a one-off visit. The healthy-aging trial used 60 sessions; the post-COVID trial used 40. A single session will not reproduce these results, and a 1.3 ATA soft-shell bag is not the equipment that generated them. Matching the evidence means matching both the pressure and the course length — a useful filter when comparing chambers from $15,000 across the market. (For the full breakdown, see hyperbaric chamber pressure levels explained.)

What HBOT Will Not Do (Yet)

Honest positioning requires naming the limits, because this is where the wellness industry overreaches.

HBOT is not FDA-cleared for cognitive enhancement, brain fog, aging, or post-COVID syndrome. Those are off-label, research-stage applications. Insurers reflect that status: payer coverage policies still classify HBOT for cognitive and post-COVID indications as investigational, despite the positive trial signal.

The evidence base also has real constraints. Much of the strongest cognition data comes from one research group (the Sagol Center in Israel), and independent replication is still limited. The effect sizes are small to medium, follow-up windows are short (assessments taken within weeks of the final session), and sample sizes are modest — 63 people in the aging trial, 73 in the post-COVID trial, 250 across the TBI meta-analysis. Whether the gains last months or years, and whether they show up as a difference patients actually notice day to day, are open questions.

And HBOT is not risk-free. Transient ear pressure and temporary, reversible changes in vision are the most common side effects, and chamber safety depends on proper equipment and oxygen handling. (See our HBOT side effects and contraindications guide.) Because brain fog can be the first sign of a treatable condition, the responsible sequence is to investigate the cause first — sleep, thyroid, mood, medications — before treating the symptom. HBOT may also pair naturally with the basics, including the sleep that the post-COVID trial saw improve.

The credible message is narrow but real: in controlled trials, HBOT has produced measurable improvements in attention, processing speed, and executive function across aging, post-COVID, TBI, and stroke populations. It is not a proven cure for brain fog, and it is not a substitute for diagnosing what is causing the fog in the first place.

What This Means for Wellness Operators

Clients are already asking about HBOT for focus, memory, and brain fog, and the honest answer is a competitive advantage. You can point to randomized, sham-controlled, and now meta-analytic evidence showing real cognitive gains — and you can decline to promise a cure the science does not support. That combination, evidence plus restraint, is exactly what discerning longevity and performance clients are looking for. Encouraging clients to rule out treatable causes first builds more trust than overpromising ever will.

The practical requirement is equipment that matches the research. Every cognition result cited here came from 2.0 ATA clinical-pressure protocols run over 40–60 sessions, which means clinical-grade hard-shell chambers, not entry-level soft-shell bags. The Superhuman T2 operates in that range, the same pressure used in the published cognition studies, and our broader approach to hyperbaric oxygen therapy is built around protocols that mirror the evidence.

If you are evaluating HBOT for a longevity, neuro-wellness, or performance practice, get in touch to discuss how the Superhuman T2 fits your space and service model, or learn more about our approach to building chambers for premium wellness environments.

References

1. Hadanny A, Daniel-Kotovsky M, Suzin G, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Aging (Albany NY). 2020;12(13):13740-13761. Aging-US
2. Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Scientific Reports. 2022;12:11252. Nature
3. Shahid S, et al. Hyperbaric oxygen therapy (HBOT) for neurocognitive deficits following traumatic brain injury: a systematic review and meta-analysis. Annals of Medicine and Surgery. 2025;87(11):7490-7498. PubMed Central
4. Hyperbaric oxygen therapy combined with computerized cognitive training improves global cognition and functional independence post-stroke: a randomized controlled trial. Journal of NeuroEngineering and Rehabilitation. 2026;23:192. Springer
5. Harvard Health Publishing. What is COVID-19 brain fog — and how can you clear it? Harvard Medical School. 2021. Harvard Health
6. Cleveland Clinic. Brain fog: what it is, causes, symptoms & treatment. Cleveland Clinic